Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial.
Selma AtalaySophie E BerendsHans M M GroenewoudRon A A MathotMarcellus D NjooJohannes M MommersPaul M OssenkoppeleMarjolein I A KoetsierMaartje A M BerendsAnnick de VriesPeter Cornelis Maria van de KerkhofAlfons A den BroederElke M G J de JongJuul M P A van den ReekPublished in: The Journal of dermatological treatment (2022)
Immunogenicity may not increase by interval prolongation in psoriasis patients with low disease activity. This pilot provides important and reassuring insight into the pharmacological changes after dose tapering of adalimumab, etanercept, and ustekinumab.
Keyphrases
- rheumatoid arthritis
- disease activity
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- systemic lupus erythematosus
- end stage renal disease
- drug induced
- ejection fraction
- study protocol
- newly diagnosed
- chronic kidney disease
- clinical trial
- prognostic factors
- peritoneal dialysis
- emergency department
- atopic dermatitis
- ulcerative colitis
- open label
- patient reported
- electronic health record